γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia

Gene Therapy

Volumn 22, Issue 4, 2015, Pages 348-355

  Friedman, G K ^a   Nan, L ^a   Haas, M C ^a   Kelly, V M ^a   Moore, B P ^a   Langford, C P ^b   Xu, H ^c   Han, X ^d   Beierle, E A ^e   Markert, J M ^b   Cassady, K A ^f   Gillespie, G Y ^b  

^a Heerskink School of Medicine   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOLYTIC HERPES VIRUS; PROTEIN KINASE R; PROTEIN KINASE; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE DELETION; GENETIC TRANSFECTION; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTIVITY; WILD TYPE; ANIMAL; CELL HYPOXIA; GENETICS; METABOLISM; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; TRANSGENIC ORGANISM; TUMOR CELL LINE;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 5;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CYTOMEGALOVIRUS; GLIOBLASTOMA; HERPESVIRUS 1, HUMAN; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ORGANISMS, GENETICALLY MODIFIED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASES; VIRAL PROTEINS;

EID: 84926406875     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.107     Document Type: Article

References (30)

1. Ries L, Melbert D, Krapcho M, Mariotto A, Miller BFeuer E et al. SEER Cancer Statistics Review. National Cancer Institute: Bethesda, MD, 2006, pp 1975-2004.
2. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 2011; 13: 317-323.
3. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
5. Cassady KA. Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection. J Virol 2000; 9: 8707-8715.
6. Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM et al. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Therapy 2007; 14: 1045-1054.
7. Markert JM, Medlock MD, Rabkin S, Gillespie G, Todo T, Hunter W et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy 2000; 7: 867-874.
8. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant) in patients with recurrent malignant glioma. Gene Therapy 2000; 7: 859-866.
9. Friedman GK, Haas MC, Kelly VM, Markert JM, Gillespie GY, Cassady KA. Hypoxia moderates γ(1)34.5-deleted herpes simplex virus oncolytic activity in human glioma Xenoline primary culture. Transl Oncol 2012; 5: 200-207.
10. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004; 64: 1886-1892.
11. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, Nelson PT et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004; 10: 8177-1884.
12. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009; 92: 317-335.
13. McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009; 7: 489-497.
14. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 3274-3284.
15. Zachos G, Koffa M, Preston CM, Clements JB, Conner J. Herpes simplex virus type 1 blocks the apoptotic host cell defense mechanisms that target Bcl-2 and manipulates activation of p38 mitogen-activated protein kinase to improve viral replication. J Virol 2001; 75: 2710-2712.
16. Mathew SS, Della Selva MP, Burch AD. Modification and reorganization of the cytoprotective cellular chaperone Hsp27 during herpes simplex virus type 1 infection. J Virol 2009; 83: 9304-9312.
17. Friedman GK, Langford C, Coleman J, Cassady KA, Parker JN, Markert JM et al. Engineered herpes simplex virus efficiently infects and kills CD133+ glioma cells that express CD111. J Neurooncol 2009; 95: 199-209.
18. Krummenacher C, Baribaud F, Ponce de Leon M, Baribaud I, Whitbeck JC, Xu R et al. Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology 2004; 322: 286-299.
19. Cowan KJ, Storey KB. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J Exp Biol 2003; 206: 1107-1115.
20. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-2849.
21. Haddad JJ, Hanbali LB. Hypoxia upregulates MAPK(p38)/MAPK(ERK) phosphorylation in vitro: neuroimmunological differential time-dependent expression of MAPKs. Protein Pept Lett 2014; 21: 444-451.
22. Yoshino Y, Aoyagi M, Tamaki M, Duan L, Morimoto T, Ohno K. Activation of p38 MAPK and/or JNK contributes to increased levels of VEGF secretion in human malignant glioma cells. Int J Oncol 2006; 29: 981-987.
23. Levin VA, Panchabhai S, Shen L, Baggerly KA. Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures. Proteome Sci 2012; 10: 5.
24. Gillis PA, Okagaki LH, Rice SA. Herpes simplex virus type 1 ICP27 induces p38 mitogen-activated protein kinase signaling and apoptosis in HeLa cells. J Virol 2009; 83: 1767-1777.
25. Zachos G, Clements B, Conner J. Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1. J Biol Chem 1999; 274: 5097-5103.
26. Zachos G, Koffa M, Preston CM, Clements JB, Conner J. Herpes simplex virus type 1 blocks the apoptotic host cell defense mechanisms that target Bcl-2 and manipulates activation of p38 mitogen-activated protein kinase to improve viral replication. J Virol 2001; 75: 2710-2728.
27. Karaca G, Hargett D, McLean TI, Aguilar JS, Ghazal P, Wagner EK et al. Inhibition of the stress-activated kinase, p38, does not affect the virus transcriptional program of herpes simplex virus type 1. Virology 2004; 329: 142-156.
28. Mezhir JJ, Advani SJ, Smith KD, Darga TE, Poon AP, Schmidt H et al. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res 2005; 65: 9479-9484.
29. Mohr I, Sternberg D, Ward S, Leib D, Mulvey M, Gluzman Y. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J Virol 2001; 75: 5189-5196.
30. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 2000; 97: 2208-2213.